secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001104659-25-039799
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent appoints Merdad Parsey to board; Carl Gordon not standing for re-election
--------------------------------------------------------------------------------

- Carl L. Gordon not standing for re-election at 2025 annual meeting (June 18); no disagreement with company.
- Board expanded from 7 to 8; Merdad Parsey (former Gilead EVP/CMO) appointed effective April 28, 2025.
- Parsey receives initial option grant of $352,000 and annual cash retainer of $45,000 plus $7,500 for committee service.
- Directors Zhengbin Yao and Kristine Peterson reclassified from Class III to Class I to balance board classes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/0001104659-25-039799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/tm2513158d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-039799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer